ArticleJournal of Cancer2019

Increase of secondary mutations may be a drug-resistance mechanism for lung adenocarcinoma after radiation therapy combined with tyrosine kinase inhibitor.

Hongqing Zhuang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.